Document is current
Any future updates will be listed below
-
Authors
Spakowicz, Daniel http://orcid.org/0000-0003-2314-6435
Hoyd, Rebecca
Muniak, Mitchell
Husain, Marium
Bassett, James S.
Wang, Lei
Tinoco, Gabriel
Patel, Sandip H.
Burkart, Jarred
Miah, Abdul
Li, Mingjia
Johns, Andrew
Grogan, Madison
Carbone, David P.
Verschraegen, Claire F.
Kendra, Kari L.
Otterson, Gregory A.
Li, Lang
Presley, Carolyn J.
Owen, Dwight H.
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (8UL1TR000090-05)
National Cancer Institute (2 P30 CA016058-42, 5K12 CA133250-09)
Pelotonia New Investigator (.)
- License Information
-
More Information
Article History
Received: 16 September 2019
Accepted: 21 April 2020
First Online: 6 May 2020
Consent for publication
: Not applicable.
: DHO has a consulting or advisory role to L&M Policy Research and AstraZeneca. DHO has research funding from Bristol-Myers Squibb, Palobiofarma, Merch Sharp & Dohme and Genentech/Roche. DHO received travel, accommodations and/or expenses from AstraZeneca. DPC is on the advisory board of Abbvie, AMGEN, Ariad, AZ, Biocept, BI, BMS, Celgene, EMD Serono, Genentech, Gritstone, Helsinn, Inivata, Inovio, Janssen, Loxo Oncology, Merck, MSD, Pfizer, Roche, Takeda, and Trinity. DPC received honoraria from AstraZeneca and Nexus Oncology. DPC is a consultant for Abbvie, Agenus, Ariad, Celgene, Genentech, Incyte, Inivata, Janssen, Kyowa Kirin, Loxo, MSD, Novartis, Pfizer and Takeda.
